Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00278343 · ClinicalTrials.gov registry record · Phase 2
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
A Phase 2 study of Recurrent Ovarian Epithelial Cancer and Recurrent Fallopian Tube Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 20
- Study locations
NCT00278343 is a Phase 2 study of Recurrent Ovarian Epithelial Cancer and Recurrent Fallopian Tube Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 74 participants, above the 44-participant average among 14 other Recurrent Ovarian Epithelial Cancer trials with a reported enrollment target (68% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT00278343, a Phase 2 study of Recurrent Ovarian Epithelial Cancer and Recurrent Fallopian Tube Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial is studying how well cediranib maleate works in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer. Cediranib maleate may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG cediranib maleate
Study Locations (20)
Illinois
- University of Chicago - Chicago
- Decatur Memorial Hospital - Decatur
- Evanston Hospital CCOP - Evanston
- Ingalls Memorial Hospital - Harvey
- Joliet Oncology-Hematology Associates Limited - Joliet
- Loyola University Medical Center - Maywood
- Peoria Gynecologic Oncology - Peoria
- Oncology/Hematology Associates - Peoria
- Central Illinois Hematology Oncology Center - Springfield
California
- City of Hope - Duarte
- University of Southern California/Norris Cancer Center - Los Angeles
- City of Hope Medical Group Inc - Pasadena
- University of California at Davis Cancer Center - Sacramento
Indiana
- Fort Wayne Medical Oncology and Hematology Inc-Parkview - Fort Wayne
- Northern Indiana Cancer Research Consortium - South Bend
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Oncology Care Associates PLLC - Saint Joseph
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
Missouri
- Saint John's Mercy Medical Center - St Louis
Pennsylvania
- University of Pittsburgh Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2006-04 |
| Est. Completion | 2018-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00278343
The ClinicalTrials.gov registry entry for NCT00278343 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 44-participant average among 14 other Recurrent Ovarian Epithelial Cancer trials with a reported enrollment target (68% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Ovarian Epithelial Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00278343 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Illinois, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT00278343 about?
NCT00278343 is a clinical study titled "Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer". This phase II trial is studying how well cediranib maleate works in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer. Cediranib maleate may stop the growth of tumor cells by blocking blood flow to the tumor and by bl...
What is the current status of trial NCT00278343?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2006-04. Estimated completion is 2018-01-15.
What conditions does trial NCT00278343 study?
This clinical trial studies the following conditions: Recurrent Ovarian Epithelial Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cavity Cancer.
What interventions are being tested in trial NCT00278343?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cediranib maleate (DRUG).
Who is sponsoring clinical trial NCT00278343?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00278343 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Epithelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
COMPLETED · Phase 2
-
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
COMPLETED · Phase 2
-
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Ovarian Epithelial Cancer
All registered trials for this condition
Recurrent Fallopian Tube Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.